Jory Bell is listed as a director on 6 SEC Form D filings by 2 issuers between Jun 2019 and Mar 2026: Strand Therapeutics Inc. (Boston, MA — biotechnology — 2019–2026; $108.1M reported sold to 13 investors) and Manifold Biotechnologies, Inc. (Boston, MA — biotechnology — 2020–2024; $40M reported sold to 13 investors).
What this means 2 separate companies raised money with this person listed as director, over about 7 years. Across those companies the filings report $148.1M sold in total.
Listed alongside Gleb Kuznetsov (3 shared filings), Jacob Becraft (3 shared filings), Pierce Ogden (3 shared filings), Tasuku Kitada (3 shared filings), Jeff Huber (2 shared filings) and 6 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Jory. Each name links to their own page.
1 of the issuers belongs to the sponsor group Fpv (4 issuers, $568.1M reported sold, 2019–2026).
What this means A sponsor group is one team that sets up a new company for each deal. Fpv has 4 companies on file and $568.1M reported sold in total — the group page shows the whole track record in one place.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 6 public filings for Jory Bell and found 8 differences, 1 worth asking the sponsor about: Form D filed 298 days after the first sale; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.